Antibiotic dosing in critically ill patients with acute kidney injury

Nature Reviews Nephrology

Volumn 7, Issue 4, 2011, Pages 226-235

  Eyler, Rachel F ^a   Mueller, Bruce A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; DAPTOMYCIN; DOPAMINE; FAMOTIDINE; FLUCONAZOLE; GENTAMICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; ITRACONAZOLE; LEVOFLOXACIN; MEROPENEM; MIDAZOLAM; NORADRENALIN; PENICILLIN G; PHENYLEPHRINE; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROPRANOLOL; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CHRONOTHERAPY; CONCENTRATION RESPONSE; CRITICALLY ILL PATIENT; DIALYSIS; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; GASTROINTESTINAL ABSORPTION; HUMAN; LIVER METABOLISM; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; URINARY EXCRETION;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; EDUCATION, MEDICAL, CONTINUING; HUMANS; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 79953169429     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.12     Document Type: Review

References (100)

1. Uchino, S. et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294, 813-818 (2005). (Pubitemid 41175724)
2. Choi, G. et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med. 37, 2268-2282 (2009).
3. Li, A. M. et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J. Antimicrob. Chemother. 64, 929-937 (2009).
4. Boucher, B. A., Wood, G. C. & Swanson, J. M. Pharmacokinetic changes in critical illness. Crit. Care Clin. 22, 255-271 (2006).
5. Stechmiller, J. K., Treloar, D. & Allen, N. Gut dysfunction in critically ill patients: a review of the literature. Am. J. Crit. Care 6, 204-209 (1997). (Pubitemid 127457725)
6. Okabe, H. et al. The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction. J. Pharm. Pharmacol. 55, 479-486 (2003). (Pubitemid 36591899)
7. Hughes, C. A. & Dowling, R. H. Speed of onset of adaptive mucosal hypoplasia and hypofunction in the intestine of parenterally fed rats. Clin. Sci. (Lond.) 5, 317-327 (1980). (Pubitemid 11214347)
8. Fagerman, K. E., McGuigan, D. & Pixley, B. Potential interaction between enteral feeding solutions and oral tetracycline. Nutr. Clin. Pract. 1, 257-258 (1986).
9. Wright, D. H., Pietz, S. L., Konstantinides, F. N. & Rotschafer, J. C. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. J. Parenter. Enteral Nutr. 24, 42-48 (2000). (Pubitemid 30027153)
10. Mueller, B. A., Brierton, D. G., Abel, S. R. & Bowman, L. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob. Agents Chemother. 38, 2101-2105 (1994). (Pubitemid 24278808)
11. Lim, S. G., Sawyerr, A. M., Hudson, M., Sercombe, J. & Pounder, E. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment. Pharmacol. Ther. 7, 317-321 (1993). (Pubitemid 23198307)
12. Fülöp, T. et al. Volume-related weight gain and subsequent mortality in acute renal failure patients treated with continuous renal replacement therapy. ASAIO J. 56, 333-337 (2010).
13. Schrier, R. W. AKI: fluid overload and mortality. Nat. Rev. Nephrol. 5, 485 (2009).
14. Mehta, R. L. et al. Nephrology consultation in acute renal failure: does timing matter? Am. J. Med. 113, 527-528 (2002).
15. Edwards, K. D. Creatinine space as a measure of total body water in anuric subjects, estimated after single injection and haemodialysis. Clin. Sci. 18, 455-464 (1959).
16. Roberts, J. A. & Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37, 840-850 (2009).
17. Tang, G. J., Tang, J. J., Lin, B. S., Kong, C. W. & Lee, T. Y. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol. Scand. 43, 726-730 (1999). (Pubitemid 29362047)
18. Roberts, J. A. et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob. Agents Chemother. 54, 3635-3640 (2010).
19. Triginer, C. et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 16, 303-306 (1990). (Pubitemid 20253465)
20. Pai, M. P. & Bearden, D. T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27, 1081-1091 (2007).
21. Falagas, M. E. & Karageorgopoulos, D. E. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375, 248-251 (2010).
22. Fry, D. The importance of antibiotic pharmacokinetics in critical illness. Am. J. Surg. 172, 20S-25S (1996). (Pubitemid 27056955)
23. Vanholder, R., Van Landschoot, N., De Smet, R., Schoots, A. & Ringoir, S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 33, 996-1004 (1988).
24. Crandon, J. L., Banevicius, M. A. & Nicolau, D. P. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob. Agents Chemother. 53, 1165-1169 (2009).
25. Meier-Hellman, A. et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit. Care Med. 25, 399-404 (1997).
26. Vilay, A. M., Churchwell, M. D. & Mueller, B. A. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit. Care 12, 235 (2008).
27. Mueller, B. A., Scarim, S. K. & Macias, W. L. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am. J. Kidney Dis. 21, 172-179 (1993). (Pubitemid 23087610)
28. Giles, L. J. et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit. Care Med. 28, 632-637 (2000). (Pubitemid 30174254)
29. Ververs, T. F. et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit. Care Med. 28, 3412-3416 (2000).
30. Macias, W. L., Mueller, B. A. & Scarim, S. K. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin. Pharmacol. Ther. 50, 688-694 (1991).
31. Pea, F., Poz, D., Viale, P., Pavan, F. & Furlanut, M. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J. Antimicrob. Chemother. 58, 380-386 (2006). (Pubitemid 44294951)
32. Pea, F., Viale, P., Pavan, F. & Furlanut, M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin. Pharmacokinet. 46, 997-1038 (2007).
33. Schmidt, C., Höcherl, K., Schweda, F. & Bucher, M. Proinflammatory cytokines cause down-regulation of renal chloride entry pathways during sepsis. Crit. Care Med. 35, 2110-2119 (2007). (Pubitemid 47326448)
34. Sun, H., Frassetto, L. & Benet, L. Z. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther. 109, 1-11 (2006). (Pubitemid 41740811)
35. Miyazaki, H., Sekine, T. & Endou, H. The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol. Sci. 25, 654-662 (2004). (Pubitemid 39458172)
36. Bergner, R. et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol. Dial. Transplant. 21, 1019-1023 (2006).
37. Schetz, M. Drug dosing in continuous renal replacement therapy: general rules. Curr. Opin. Crit. Care 13, 645-651 (2007). (Pubitemid 350059527)
38. Joy, M. S., Matzke, G. R., Frye, R. F. & Palevsky, P. M. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am. J. Kidney Dis. 31, 1019-1027 (1998). (Pubitemid 28265200)
39. Clark, W. R. & Ronco, C. CRRT efficiency and efficacy in relation to solute size. Kidney Int. Suppl. 72, S3-S7 (1999).
40. Churchwell, M. D. & Mueller, B. A. Drug dosing during continuous renal replacement therapy. Semin. Dial. 22, 185-188 (2009).
41. Bouman, C. S. et al. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med. 32, 2013-2019 (2006). (Pubitemid 44833115)
42. Golper, T. A. Drug removal during continuous hemofiltration or hemodialysis. Contrib. Nephrol. 93, 110-116 (1991).
43. Uchino, S. et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Intensive Care Med. 33, 1563-1570 (2007).
44. Jeffrey, R. F. et al. A comparison of molecular clearance rates during continuous hemofiltration and hemodialysis with a novel volumetric continuous renal replacement system. Artif. Organs 18, 425-428 (1994). (Pubitemid 24179871)
45. Huang, Z., Letteri, J. J., Clark, W. R., Ronco, C. & Gao, D. Operational characteristics of continuous renal replacement modalities used for critically ill patients with acute kidney injury. Int. J. Artif. Organs 31, 525-534 (2008).
46. DeSoi, C. A., Sahm, D. F. & Umans, J. G. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am. J. Kidney Dis. 20, 354-360 (1992).
47. Agarwal, R. & Toto, R. D. Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers. Am. J. Kidney Dis. 22, 296-299 (1993). (Pubitemid 23236637)
48. Scott, M. K., Mueller, B. A. & Clark, W. R. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol. Dial. Transplant. 12, 2647-2653 (1997). (Pubitemid 27520689)
49. Ahern, J. W., Lai, C., Rebuck, J. A., Possidente, C. J. & Weidner, M. Experience with vancomycin in patients receiving slow low efficiency dialysis. Hosp. Pharm. 39, 138-143 (2004). (Pubitemid 38197502)
50. Fiaccadori, E. et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit. Care Med. 32, 2437-2442 (2004). (Pubitemid 39648225)
51. Choi, G. et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration: an in vitro study of levofloxacin. Int. J. Antimicrob. Agents 24, 468-472 (2004). (Pubitemid 39425159)
52. Tian, Q. et al. Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. Int. J. Antimicrob. Agents 28, 147-150 (2006). (Pubitemid 44108618)
53. Uchino, S., Cole, L., Morimatsu, H., Goldsmith, D. & Bellomo, R. Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med. 28, 1664-1667 (2002). (Pubitemid 36002520)
54. Clark, W. R., Turk, J. E., Kraus, M. A. & Gao, D. Dose determinants in continuous renal replacement therapy. Artif. Organs 27, 815-820 (2003). (Pubitemid 37108622)
55. Mueller, B. A., Pasko, D. A. & Sowinski, K. M. Higher renal replacement therapy dose delivery influences on drug therapy. Artif. Organs 27, 808-814 (2003). (Pubitemid 37108621)
56. Aronoff, G. R. et al. Drug prescribing in renal failure: dosing guidelines for adults and children 5th edn (American College of Physicians, Philadelphia, 2007).
57. Ambrose, P. G. et al. Pharmacokinetics: pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44, 79-86 (2007). (Pubitemid 44968990)
58. Owens, R. C. Jr & Shorr, A. F. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am. J. Health Syst. Pharm. 66, S23-S30 (2009).
59. Bhavnani, S. M., Rubino, C. M., Ambrose, P. G. & Drusano, G. L. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50, 1568-1574 (2010).
60. Vilay, A. M. et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit. Care Med. 39, 19-25 (2011).
61. Churchwell, M. D., Pasko, D. A. & Mueller, B. A. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 24, 548-554 (2006). (Pubitemid 46030098)
62. Turnidge, J. Pharmacodynamics and dosing of aminoglycosides. Infect. Dis. Clin. North Am. 17, 503-528 (2003). (Pubitemid 38029150)
63. Beaucaire, G. et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J. Antimicrob. Chemother. 27 (Suppl. C), 91-103 (1991).
64. Marik, P. E., Lipman, J., Kobilski, S. & Scribante, J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J. Antimicrob. Chemother. 28, 753-764 (1991).
65. Kielstein, J. T. et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol. Dial. Transplant. 25, 1537-1541 (2010).
66. Perrott, J., Mabasa, V. H. & Ensom, M. H. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann. Pharmacother. 44, 557-564 (2010).
67. Langgartner, J., Vasold, A., Glück, T., Reng, M. & Kees, F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 34, 1091-1096 (2008). (Pubitemid 351903794)
68. Mariat, C. et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit. Care 10, R26 (2006).
69. Roberts, J. A. et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int. J. Antimicrob. Agents 36, 332-339 (2010).
70. Schetz, M. Drug dosing in continuous renal replacement therapy: general rules. Curr. Opin. Crit. Care 13, 645-651 (2007). (Pubitemid 350059527)
71. Choi, G. et al. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif. 30, 195-212 (2010).
72. Reetze-Bonorden, P., Böhler, J. & Keller, E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin. Pharmacokinet. 24, 362-379 (1993). (Pubitemid 23135684)
73. Kroh, U. F. Drug administration in critically ill patients with acute renal failure. New Horiz. 3, 748-759 (1995).
74. Mueller, B. A. & Smoyer, W. E. Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy. Clin. Pharmacol. Ther. 86, 479-482 (2009).
75. Li, A. M. et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J. Antimicrob. Chemother. 64, 929-937 (2009).
76. Wingender, W. et al. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur. J. Clin. Microbiol. 3, 355-359 (1984). (Pubitemid 14034601)
77. Fish, D. N., Bainbridge, J. L. & Peloquin, C. A. Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration. Pharmacotherapy 15, 236-245 (1995).
78. Wallis, S. C., Mullany, D. V., Lipman, J., Rickard, C. M. & Daley, P. J. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous hemodiafiltration. Intensive Care Med. 27, 665-672 (2001). (Pubitemid 32304570)
79. Chien, S. C. et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41, 2256-2260 (1997).
80. Chow, A. T. et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45, 2122-2125 (2001). (Pubitemid 32591709)
81. Malone, R. S., Fish, D. N., Abraham, E. & Teitelbaum, I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother. 45, 2949-2954 (2001). (Pubitemid 32906702)
82. Guenter, S. G., Iven, H., Boos, C., Bruch, H. P. & Muhl, E. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy 22, 175-183 (2002). (Pubitemid 34112880)
83. Lode, H., Grunert, K., Koeppe, K. P. & Langmaack, H. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J. Infect. Dis. 134, S316-S322 (1976).
84. Kinowski, J. M. et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob. Agents Chemother. 37, 464-473 (1993).
85. Benvenuto, M., Benziger, D. P., Yankelev, S. & Vigliani, G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50, 3245-3249 (2006). (Pubitemid 44527494)
86. Nilsson-Ehle, I., Hutchison, M., Haworth, S. J. & Norrby, S. R. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10, 85-88 (1991).
87. Krueger, W. A. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother. 49, 1881-1889 (2005). (Pubitemid 40631603)
88. Dreetz, M. et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob. Agents Chemother. 40, 105-109 (1996). (Pubitemid 26019685)
89. Krueger, W. A. et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob. Agents Chemother. 42, 2421-2424 (1998). (Pubitemid 28420389)
90. Occhipinti, D. J. et al. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob. Agents Chemother. 41, 2511-2517 (1997). (Pubitemid 27467565)
91. Capellier, G. et al. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit. Care Med. 26, 88-91 (1998). (Pubitemid 28028445)
92. van der Werf, T. S., Mulder, P. O., Zijlstra, J. G., Uges, D. R. & Stegeman, C. A. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med. 23, 873-877 (1997). (Pubitemid 27417691)
93. Blouin, R. A., Bauer, L. A., Miller, D. D., Record, K. E. & Griffen, W. O. Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21, 575-580 (1982). (Pubitemid 12070524)
94. Healy, D. P., Polk, R. E., Garson, M. L., Rock, D. T. & Comstock, T. J. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 31, 393-397 (1987). (Pubitemid 17027127)
95. Boeckh, M. et al. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob. Agents Chemother. 32, 92-95 (1988). (Pubitemid 18025684)
96. Kielstein, J. T. et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med. 34, 51-56 (2006). (Pubitemid 43032379)
97. Dot, M. E., Lipman, J. & Tett, S. E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br. J. Clin. Pharmacol. 58, 259-268 (2004). (Pubitemid 39209059)
98. Trotman, R. L., Williamson, J. C., Shoemaker, D. M. & Salzer, W. L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41, 1159-1166 (2005). (Pubitemid 41429480)
99. Heintz, B. H., Matzke, G. R. & Dager, W. E. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29, 562-577 (2009).
100. Gilbert, D. N. (Ed.) The Sanford Guide to Antimicrobial Therapy 40th edn (Sanford, Sperryville, 2010)